Roswell Park Announces Positive Progress in Clinical Trial of Novel Immunotherapy SurVaxM

Roswell Park Comprehensive Cancer Center today announced that the ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data. 

Read More